EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
EYPT Stock Chart & Stats
$13.05
$0.01(0.11%)
At close: 4:00 PM EST
$13.05
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$3.91 - $19.11
Previous CloseN/A
Volume354.62K
Average Volume (3M)1.64M
Market Cap
$1.09B
Enterprise Value$1.01B
Total Cash (Recent Filing)$306.09M
Total Debt (Recent Filing)$20.77M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
May 06, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding83,431,950
10 Day Avg. Volume1,087,452
30 Day Avg. Volume1,636,087
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.37
Price to Sales (P/S)42.66
P/FCF Ratio-5.50
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue32.15
Enterprise Value/Gross Profit34.42
Enterprise Value/Ebitda-4.21
Forecast
1Y Price Target
$36.60Price Target Upside180.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.22
Revenue Forecast (FY)$3.79M
Bulls Say, Bears Say
Bulls Say
Pivotal Trial ProgressCompletion of enrollment in the wet AMD Phase 3 program and independent monitoring committees recommending continuation support clear pivotal readouts that could drive regulatory filings and value inflection.
Regulatory PathwayTrial designs aligned with U.S. and European regulatory guidance and the potential for a single robust Phase 3 to support approval may streamline the review process and reduce regulatory uncertainty.
Therapeutic DifferentiationDuravyu's dual targeting of VEGF-driven vascular leakage and IL-6–mediated inflammation could provide broader vision benefits than single‑mechanism treatments, increasing its competitive appeal for difficult-to-treat patients.
Bears Say
Commercial Adoption ConstraintsCost pressures and anticipated payor restrictions could confine tyrosine kinase inhibitor use to previously treated, hard-to-treat patients, limiting broad market uptake and revenue potential.
Financial Strain And DilutionA large annual net loss highlights substantial clinical-development spending and raises the possibility of future capital raises that could dilute existing shareholders if commercial milestones are delayed.
Safety RiskObserved intraocular inflammation, visually significant floaters, and cataract progression in some cases create a risk that safety signals could limit physician adoption compared with established therapies.
EyePoint Pharmaceuticals News
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $3.91 and its highest was $19.11 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
EyePoint Pharmaceuticals Inc’s market cap is $1.09B.
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is May 06, 2026 which is in 40 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Mar 04, 2026. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.748 by -$0.062.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -0.82.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 83,431,950 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.748. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in EYPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EyePoint Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.60 (180.46% Upside)
$36.60 (180.46% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 200.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $787.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
109.13%
12-Months-Change
Fundamentals
Return on Equity
-88.31%
Trailing 12-Months
Asset Growth
-13.02%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
EYPT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive clinical and commercial story centered on rapid Phase 3 progress (wet AMD readouts mid-2026, DME pivotal dosing underway), a differentiated multi-mechanistic asset with promising Phase 2 efficacy and a clean safety profile in ~190 patients, along with manufacturing and commercial hires to support a potential launch. Offsetting these positives are material financial headwinds from sharply lower quarter and year revenues, substantially higher operating expenses and an increased net loss, with cash down year-over-year though raised financing provides runway into 2027. Regulatory/commercial execution and continued safety monitoring remain key near-term risks. Overall, the positive clinical momentum and adequate near-term funding tip the balance toward a favorable outlook despite clear financial burn and execution risks.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$36.60
▲(180.46% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
10.81% Insiders
17.72% Mutual Funds
51.17% Other Institutional Investors
8.74% Public Companies and
Individual Investors